Skip to main content

Table 3 Incidence of Treatment-related Adverse Events in the Study Population for Each Cohort

From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Adverse Event NCI CTC Severity Grade Dose Cohort Total
   250 mg 500 mg 750 mg 850 mg 1000 mg   
   No. % No. % No. % No. % No. % No. %
Hypertension 1-2 2 50 7 63.6 9 60 9 69.2 2 66.7 29 63
  3-4 - -    2 13.3 - - 1 33.3 3 6.5
Proteinuria 1-2 - - 4 36.4 7 46.67 5 38.5 -   16 34.8
  3-4 1 25.0 1 9 3 20 1 7.7 - - 6 13
Hand-Food Syndrome 1-2 - - 4 36.4 7 46.7 4 30.8 - - 15 32.6
  3-4 - - 1 9 2 13.3 2 15.4 1 33.3 6 13
Pain 1-2 - - 4 36.4 4 26.7 3 23.1 1 33.3 12 26.1
  3-4 - - 2 18.2 2 13.3 - - - - 4 8.7
Thrombocytopenia 1-2 1 25.0 2 18.2 6 40 2 15.4 1 33.3 12 26.1
  3-4 - - 0 0 - - 1 7.7 - - 1 2.2
Fatigue 1-2 - - 1 9 4 26.7 4 30.8 1 33.3 10 21.7
  3-4 - - - - 1 6.7 - - 1 33.3 2 4.3
Hyperbilirubinemia 1-2 - - - - - - 3 23.1 - - 3 6.5
  3-4 1 25 - - - - - - - - 1 2.2
Transaminase Increased 1-2 2 50.0 1 9 6 40 3 23.1 1 33.3 13 28.3
  3-4 - - 1 9 - - 2 15.4 1 33.3 4 8.7
Hemorrhage 1-2 - - 4 36.4 5 33.3 1 7.7 - - 10 21.7
  3-4 - - 1 9 - - - - - - 1 2.2
Neutropenia 1-2 - - 2 18.2 7 46.7 4 30.8 3 100 16 34.8
  3-4 - - 2 18.2 - - 2 15.4 - - 4 8.7
Diarrhea 1-2 - - 1 9 3 20 2 15.4 - - 6 13
  3-4 - - - - - - - - - - - -
Mucosal ulcers 1-2 - - 2 18.2 2 13.3 2 15.4 2 66.7 8 17.4
  3-4 - - - - 2 13.3 - - - - 2 4.3
Infection 1-2 1 25.0 1 9 4 26.7 3 23.1 1 33.3 10 21.7
  3-4 - - - - - - - - - - - -
Dyspnea 1-2 - - - - - - 1 7.7 - - 1 2.2
  3-4 - - - - - - - - - - - -
Vomiting 1-2 - - 0 0 4 26.7 - - - - 4 8.7
  3-4 - - - - - - 1 7.7 - - 1 2.2
Hoarseness 1-2 - - 1 9 2 13.3 1 7.7 - - 4 8.7
  3-4 - - - - - - - - - - - -
Albinism 1-2 - - - - 1 6.7 - - - - 1 2.2
  3-4 - - - - - - - - - - - -
Anemia 1-2 1 25.0 1 9 3 20 2 15.4 - - 7 15.2
  3-4 - - - - - - 1 7.7 1 33.3 2 4.3
Rash 1-2 - - 1 9 1 6.7 1 7.7 - - 3 6.5
  3-4 - - - - - - - - - - - -
Anorexia 1-2 - - 2 18.2 3 20 1 7.7 1 33.3 7 15.2
  3-4 - - - - - - - - - - - -
  1. Abbreviations: AE, adverse event; NCI CTC, National Cancer Institute Common Toxicity Criteria